Cellular’s neuropsychiatric assets is Caplyta, a pill approved for schizophrenia and bipolar depression and proposed for major depressive disorder.

Passage Bio’s workforce reduction could affect about 32 people, leaving the company with 26 employees as it continues ...

Benefiting from technological and conceptual groundwork and positive early data, gene therapies are advancing in the clinic ...

Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming ...

Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...

Science has been our calling from the beginning. Colonel Eli Lilly founded the company in 1876 and charged employees to “take what you find here and make it better and better.” More than 147 years ...

Biogen’s proposed acquisition comes after two difficult years of regulatory and clinical challenges, during which shares of ...

Emraclidine was the centerpiece of AbbVie’s $8.7 billion acquisition of Cerevel in December 2023 but failed two mid-stage ...